IPHYF supply chain intelligence for Innate Pharma SA: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Innate Pharma SA (IPHYF) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| NVO | Novo Nordisk A/S | 72% | uding fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. The table does not include obligations under ag… |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from IPHYF graph: uding fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing o… |
| SNYNF | Sanofi | 72% | ortfolio including an approved product, four clinical product candidates and a robust preclinical pipeline. We have entered into collaborations with leaders in the biopharmaceutical industry, such as… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from IPHYF graph: ortfolio including an approved product, four clinical product candidates and a robust preclinical pipeline. We have… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| IPHA | Innate Pharma S.A. | 72% | Reciprocal relationship from IPHA graph: Reciprocal relationship from IPHYF graph: Reciprocal relationship from IPHA graph: Reciprocal relationship from IPHYF graph: location of prior period loss — —… |
| IPHA | Innate Pharma S.A. | 72% | location of prior period loss — — — ( ) — Exercise and subscription of equity instruments — — — Increase capital, net — — — — — — Share-based payment — — December 31, 2021 ( ) ( ) (1) (2) F-8 NOTES T… |
| NVO | Novo Nordisk A/S | 72% | t of lump sums and royalties on sales to the licensor. The timing of the obligations depends on when related milestones are reached, which cannot be anticipated. 189 We also signed option agreements … |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from IPHYF graph: Reciprocal relationship from NVO graph: Reciprocal relationship from IPHYF graph: t of lump sums and royalties on sal… |
| SNGX | Soligenix, Inc. | 72% | Reciprocal relationship from SNGX graph: Reciprocal relationship from IPHYF graph: Reciprocal relationship from SNGX graph: Reciprocal relationship from IPHYF graph: Reciprocal relationship from SNGX… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from IPHYF graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IPHYF graph: Reciprocal relationship from SN… |
| SNYNF | Sanofi | 72% | ortfolio including an approved product, four clinical product candidates and a robust preclinical pipeline. We have entered into collaborations with leaders in the biopharmaceutical industry, such as… |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| SNYNF | Sanofi | 100.00 | 1 | ['customer', 'supplier'] |
| SNGX | Soligenix, Inc. | 100.00 | 1 | ['customer'] |
| NVO | Novo Nordisk A/S | 100.00 | 1 | ['customer', 'supplier'] |
| ANL | Adlai Nortye Ltd. | 50.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 50.00 | 2 | |
| CRVS | Corvus Pharmaceuticals, Inc. | 50.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 50.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 50.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 50.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 50.00 | 2 | |
| DNTH | Dianthus Therapeutics, Inc. | 50.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 50.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 50.00 | 2 | |
| AZN | AstraZeneca PLC | 50.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 50.00 | 2 | |
| CLDX | Celldex Therapeutics, Inc. | 50.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 50.00 | 2 | |
| LGND | Ligand Pharmaceuticals Incorporated | 50.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 50.00 | 2 | |
| CANF | Can-Fite BioPharma Ltd. | 50.00 | 2 |